Page last updated: 2024-12-08
stenbolone
Description
stenbolone: structure given in first source; RN given from Merck; RN given refers to the (5alpha,17beta)-isomer; RN for cpd without isomeric designation not available 7/91 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 234454 |
| CHEBI ID | 34980 |
| SCHEMBL ID | 145680 |
| MeSH ID | M0188669 |
Synonyms (31)
| Synonym |
|---|
| stenbolonum [inn-latin] |
| estembolona [inn-spanish] |
| estembolona |
| stenbolone [inn] |
| 17beta-hydroxy-2-methyl-5alpha-androst-1-en-3-on |
| nsc 65890 |
| androst-1-en-3-one, 17-hydroxy-2-methyl-, (5alpha,17beta)- |
| 3q6fka848s , |
| unii-3q6fka848s |
| nsc 34418 |
| stenbolonum |
| nsc-34418 |
| nsc34418 |
| deacetylanatrofin |
| 5197-58-0 |
| stenbolone |
| 5.alpha.-androst-1-en-3-one, 17.beta.-hydroxy-2-methyl- |
| LMST02020044 |
| 17beta-hydroxy-2-methyl-5alpha-androst-1-en-3-one |
| nsc65890 |
| nsc-65890 |
| (5s,8r,9s,10s,13s,14s,17s)-17-hydroxy-2,10,13-trimethyl-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one |
| stenbolone [mart.] |
| stenbolone [mi] |
| 17.beta.-hydroxy-2-methyl-5.alpha.-androst-1-en-3-one |
| SCHEMBL145680 |
| CS-4516 |
| CHEBI:34980 |
| HY-16971 |
| DTXSID70199935 |
| Q7607492 |
Roles (1)
| Role | Description |
|---|
| androgen | A sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
| Class | Description |
|---|
| 3-hydroxy steroid | Any hydroxy steroid carrying a hydroxy group at position 3. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 51.28
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 51.28 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.66 (4.65) | | Search Engine Demand Index | 73.99 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 1 (20.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (20.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |